Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
BörsenkürzelSMLR
Name des UnternehmensSemler Scientific Inc
IPO-datumFeb 27, 2014
CEOMurphy Chutorian (Douglas)
Anzahl der mitarbeiter79
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 27
Addresse51 E Campbell Ave
StadtCAMPBELL
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl95008
Telefon18777744211
Websitehttps://www.semlerscientific.com/
BörsenkürzelSMLR
IPO-datumFeb 27, 2014
CEOMurphy Chutorian (Douglas)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten